Arts-de Jong M, Maas A H E M, Massuger L F, Hoogerbrugge N, de Hullu J A
Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Crit Rev Oncol Hematol. 2014 Aug;91(2):159-71. doi: 10.1016/j.critrevonc.2014.01.008. Epub 2014 Jan 24.
BRCA1/2 mutation carriers have an elevated risk of developing breast and ovarian cancer at a relatively young age. Risk-reducing salpingo-oophorectomy is an established strategy to tremendously reduce the risk of ovarian cancer. It is recommended to perform this surgery at age 35-40 years (BRCA1) and at age 40-45 years (BRCA2) resulting in an early and abrupt menopause. BRCA1/2 mutation carriers are potentially at higher risk of cardiovascular diseases due to early surgical menopause, and cardiotoxic effects of adjuvant treatment for breast cancer. Furthermore, preliminary results of experimental studies suggest a possible causative function of the BRCA genes in cardiovascular risk. More research on cardiovascular health risks in BRCA1/2 mutation carriers is needed, especially in the field of cardio-oncology, requiring additional attention to potentially cumulative effects on cardiovascular risks in this specific group of women.
BRCA1/2基因变异携带者在相对年轻时患乳腺癌和卵巢癌的风险会升高。降低风险的输卵管卵巢切除术是一种已确立的可大幅降低卵巢癌风险的策略。建议在35 - 40岁(BRCA1)和40 - 45岁(BRCA2)时进行该手术,这会导致早期和突然绝经。由于早期手术绝经以及乳腺癌辅助治疗的心脏毒性作用,BRCA1/2基因变异携带者患心血管疾病的潜在风险更高。此外,实验研究的初步结果表明BRCA基因在心血管风险中可能具有致病作用。需要对BRCA1/2基因变异携带者的心血管健康风险进行更多研究,尤其是在心脏肿瘤学领域,需要特别关注对这一特定女性群体心血管风险的潜在累积影响。